Skip to main content

Exercise tolerance with nebivolol and atenolol

Cardiovascular Drugs and Therapy volume 6, pages 239–247 (1992)Cite this article

Summary

Patients treated with beta-blocking agents often complain of fatigue during exercise. Exercise capacity is decreased under this condition. Nebivolol is a new beta1-adrenoceptor antagonist with a particular hemodynamic profile, which might be due to an ancillary property. Five milligrams once daily seems the optimal dose for antihypertensive treatment. In a double-blind, placebo-controlled crossover study, the effects of nebivolol on maximal and endurance exercise capacity are compared with those of atenolol in healthy volunteers. The hemodynamic and metabolic effects during exercise are also studied. Nebivolol 5 mg once daily and atenolol 100 mg once daily decrease blood pressure at rest similarly. At these dosages nebivolol shows a smaller decrease in heart rate than atenolol. During exercise, the rise in systolic blood pressure and heart rate is less depressed with nebivolol than with atenolol. In contrast to atenolol, nebivolol does not decrease maximal and endurance exercise capacity, and does not increase perceived exertion significantly. Changes in hemodynamics influence maximal exercise capacity. Since nebivolol has less effect on exercise hemodynamics than atenolol, this might explain why maximal work capacity is not changed during nebivolol. During endurance exercise metabolic effects are thought to be more important. Under nebivolol glycerol and NEFA production is less depressed during exercise and might explain the preserved endurance capacity. These data suggest less beta blockade during nebivolol than during atenolol at the dosages used in this study. In conclusion, at a dose known to be antihypertensive, nebivolol does not alter exercise capacity significantly in healthy volunteers.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Franz I-W, Lohmann FW, Koch G. Effects of chronic antihypertensive treatment with acebutolol and pindolol on blood pressures, plasma catecholamines and oxygen uptake at rest and during submaximal and maximal exercise. J Cardiovasc Pharmacol 1982;4:180–186.

    Google Scholar 

  2. Smyth GA, Hughson RL, Walters DJ, Ranney DA. Short-versus long-term effects of oral beta-blockers on exercise performance. J Cardiac Rehab 1984;4:227–237.

    Google Scholar 

  3. Van Baak MA, Jennen W, Verstappen FTJ. Maximal aerobic power and blood pressure in normotensive subjects after acute and chronic administration of metoprolol. Eur J Clin Pharmacol 1985;28:143–148.

    Google Scholar 

  4. Szlacheic J, Hirsch AT, Tubau JF, et al. Diltiagem versus propranolol in essential hypertension: Responses of rest and exercise blood pressure and effects on exercise capacity. Am J Cardiol 1987;59:393–399.

    Google Scholar 

  5. Van Baak MA, Koene FMM, Verstappen FTJ. Exercise hemodynamics and maximal exercise capacity during beta-blockade in normotensive and hypertensive subjects. Br J Clin Pharmacol 1988;25:169–178.

    Google Scholar 

  6. Galbo H, Holst JJ, Christensen NJ, Hilsted J. Glucagon and plasma catecholamines during beta-receptor blockade in exercising man. J Appl Physiol 1976;40:855–863.

    Google Scholar 

  7. Lundborg P, Aström H, Bengtsson C, et al. Effect of beta-adrenoceptor blockade on exercise performance and metabolism. Clin Sci 1981;61:299–305.

    Google Scholar 

  8. Kullmer T, Kindermann W, Singer M. Effects on physical performance of intrinsic sympathicomimetic activity (ISA) during selective beta-blockade. Eur J Appl Physiol 1987; 56:292–298.

    Google Scholar 

  9. Van Baak MA, Böhm ROB, Arends BG, et al. Long-term antihypertensive therapy with beta-blockers: Submaximal exercise capacity and metabolic effects durign exercise. Int J Sports Med 1987;8:342–374.

    Google Scholar 

  10. Van Baak MA, Böhm ROB, Petri J, Rahn KH. Metabolic effects of verapamil and propranolol during submaximal endurance exercise in patients with essential hypertension. Int J Sports Med 1987;8:270–274.

    Google Scholar 

  11. Cléroux J, Van Nguyen P, Taylor AW, Leenen FHH. Effects of β1 vs β1 + β2 blockade on exercise endurance and on muscle metabolism in humans. J Appl Physiol 1989; 66:548–554.

    Google Scholar 

  12. Vanhees L, Fagard R, Lijnen P, Amery A. Effect of antihypertensive medication on endurance exercise capacity in sporting hypertensive patients. Fifth European Meeting on Hypertension, 1991; abstr no 752.

  13. Sahlin K. Metabolic changes limiting muscle performance. In: Saltin B, ed. Biochemistry of exercise. VI. International series on sport sciences, vol 16. Champaign, IL: Human Kinetics, 1986;323–343.

    Google Scholar 

  14. Van de Water A, Janssens W, Van Nueten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharmacol 1988;11:552–563.

    Google Scholar 

  15. Schnaper H, Jackson D, Sit SP. Nebivolol: A new generation of β-blockers in hypertension. Am J Hypertens 1991;4:23A.

  16. Sieben G, Van Nueten L, Symoens J. Nebivolol in hypertension. Drug Invest 1991;3(Suppl 1):190–192.

    Google Scholar 

  17. Sanchez RA, Cianciulli T, Dopico AM, et al. Effects of nebivolol on left ventricular function in patients with essential hypertension. Drug Invest 1991;3(Suppl 1):155–160.

    Google Scholar 

  18. Collier CR. Determination of mixed venous CO2 tensions by rebreathing. J Appl Physiol 1956;9:25–29.

    Google Scholar 

  19. Jones NL, Campbell EJM, McHardy GIR, et al. The estimation of carbon dioxide pressure of mixed venous blood during exercise. Clin Sci 1967;32:311–327.

    Google Scholar 

  20. van Herwaarden CLA, Binkhorst RA, Fennis JFM, Van't Laar A. Reliability of the cardiac output measurement with the indireet Fick principle for CO2 during exercise. Pflügers Arch 1980;385:21–23.

    Google Scholar 

  21. Inman MD, Hughson RL, Jones NL. Comparison of cardiac output during exercise by single breath and CO2 rebreathing methods. J Appl Physiol 1985;58:1372–1377.

    Google Scholar 

  22. Costill DL, Fink WJ. Plasma volume changes following exercise and thermal dehydration. J Appl Physiol 1974;37: 521–525.

    Google Scholar 

  23. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehab Med 1970;2:92–98.

    Google Scholar 

  24. Duncombe MG. The colorimetric micro-determination of non-esterified fatty acids in plasma. Clin Chim Acta 1964; 9:122–125.

    Google Scholar 

  25. Weddle OH, Amick EN, Mason WD. Rapid determination of antenolol in plasma and urine by high-performance liquid chromatography. J Pharmac Sci 1978;67:1033–1035.

    Google Scholar 

  26. Woestenborghs R, Embrechts L, Heykants J. HPLC-fluorescence method for the determination of the new beta-1 adrenoceptor blocking agent nebivolol in human plasma. In: Reid E et al., eds. Bioanalysis of drug and metabolites, especially anti-inflammatory and cardiovascular. New York: Plenum Press, 1988:215–216.

    Google Scholar 

  27. Zerbe GD. Randomization analysis of randomized blocks design extended to growth and response curves. Commun Stat Theor Met 1979;A8:191–205.

    Google Scholar 

  28. Van Baak MA. Beta-adrenoceptor blockade and exercise. An update. Sports Med 1988;4:209–225.

    Google Scholar 

  29. Mooij J, Van Baak M, Böhm R, et al. The effects of verapamil and propranolol on exercise tolerance in hypertensive patients. Clin Pharmacol Ther 1987;41:490–495.

    Google Scholar 

  30. Van Baak MA, Mooij JMV, Wijnen JAG, Tan ES. Submaximal endurance exercise performance during enalapril treatment in patients with essential hypertension. Clin Pharmacol Ther 1991;50:221–227.

    Google Scholar 

  31. Van Baak MA, Koene FMM, Verstappen FTJ, Tan ES. Exercise performance during captopril and atenolol treatment in hypertensive patients. Br J Clin Pharmacol 1991; 32:723–728.

    Google Scholar 

  32. Van Baak MA, Verstappen FTJ, Oosterhuis B. Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion. Eur J Clin Pharmacol 1986;30:399–406.

    Google Scholar 

  33. Katz A, Sahlin K, Juhlin-Dannfelt A. Effect of betaadrenoceptor blockade on H+ and K+ flux in exercising humans. J Appl Physiol 1985;59:336–341.

    Google Scholar 

  34. Kullmer T, Kinderman W. Physical performance and serum potassium under chronic beta-blockade. Eur J Appl Physiol 1985;54:350–354.

    Google Scholar 

  35. Leenen FH, Coenen CHM, Zonderland M, Maas AHJ. Effects of cardioselective and nonselective beta-blockade on dynamic exercise performance in mildly hypertensive men. Clin Pharmacol Ther 1980;28:12–21.

    Google Scholar 

  36. Sjøgaard G, Adams RP, Saltin B. Water and ion shifts in skeletal muscle of humans with intense dynamic knee extension. Am J Physiol 1985;248:R190-R196.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, Department of Pharmacology, University of Limburg, Maastricht, The Netherlands

    Luc M. A. B. Van Bortel & Marleen A. van Baak

Authors
  1. Luc M. A. B. Van Bortel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marleen A. van Baak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Van Bortel, L.M.A.B., van Baak, M.A. Exercise tolerance with nebivolol and atenolol. Cardiovasc Drug Ther 6, 239–247 (1992). https://doi.org/10.1007/BF00051145

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00051145

Key Words

  • exercise tolerance
  • perceived exertion
  • quality of life
  • maximal exercise
  • endurance performance
  • nebivolol
  • atenolol